Emerging Therapy

Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of Service and Privacy Policy.

Emerging Therapy

Optimism Grows for Toddlers with Peanut Allergies as Viaskin Patch Safety Study Begins

Study to Reduce Infants’ Life-Threatening Food Allergies at Risk Due to Federal Cuts

FAF Funding Four New Food Allergy Research Projects Working Toward Finding Treatments and a Cure

Dupilumab Lowered IgE Levels in Small Study

Children’s Response to Peanut Patch Therapy Increased Over 60 Months

Update on Delivery of Emergency Epinephrine via Sublingual Film

FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

Aimmune Therapeutics Presents New AR101 Data Including Demonstrated Reduction in Accidental...

FDA Fast Tracks ARS-1 Intranasal Epinephrine Spray

Study: Treatment with Omalizumab Raises Tolerance in Patients with Severe Food...

DBV to Resubmit Application to FDA for Viaskin Peanut Approval in...

Government Shutdown Delays Review of AR101 Peanut Oral Immunotherapy Candidate

Company Developing Microbiome-Derived Food Allergy Therapy Raises $27 Million

Aimmune Submits FDA Application to Offer AR101 for the Treatment of...

DBV Withdraws FDA Application for Viaskin Peanut with Plan to Resubmit

Your School On Our Map

Put Your School on the Map